Abstract
Purpose. Population models for thepharmacokinetic-pharmacodynamic relationship for cetrorelix (CET), a luteinising hormone-releasinghormone (LH-RH) antagonist, and the pharmacodynamic response ontestosterone production were investigated in rats and dogs.
Methods. The plasma concentrations of CET and testosterone weredetermined after intravenous and subcutaneous injections. Thepopulation PK/PD-models were developed using P-PHARM software.
Results. Absolute bioavailability of cetrorelix was 100% in rats and97% in dogs. In rats, the pharmacokinetics was explained by atwo-compartment model with saturable absorption, while athree-compartment model was used in dogs. Testosterone suppression in both specieswas described by a sigmoid Emax model with maximum effect (Emax)considered as total hormonal suppression. The duration of testosteronesuppression in rats was longer at higher doses. The populationelimination half-lifes after iv-dose were 3.0 h in rats and 9.3 h in dogs.Population mean estimates of IC50 were 1.39 and 1.24 ng/ml in ratsand dogs, respectively.
Conclusions. A population pharmacokinetic model was developed toexplain the dissolution rate limited absorption from the injection site.The suppression of testosterone could be described by an indirectinhibitory sigmoid Emax model. In both species 1-2 ng/ml CET inplasma was necessary to suppress testosterone production.
Similar content being viewed by others
REFERENCES
E. Knobil. The neuroendocrine control of the menstrual cycle. Recent Prog. Horm. Res., 36:53-80 (1980).
S. Fukuda. Circadian rhythm of serum testosterone levels in male beagle dogs-effects of lightning time zone. Exp. Anim., 39(1):65-68 (1990).
L. R. DePalatis, J. Moore, and R. E. Falvo. Plasma concentrations of testosterone and LH in the male dog. J. Reprod. Fert., 52: 201-207 (1978).
S. Bajusz, M. Kovacs, M. Gazdag, L. Bokser, T. Karashima, V. J. Csernus, T. Janaky, J. Guoth, and A. V. Schally. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc. Natl. Acad. Sci. USA 85:1637-1641 (1988).
M. Schwahn, P. Romeis, G. Peter, H. Derendorf, and M. Herbst. Absolute bioavailability and dose proportionality of CET, a novel LH-RH antagonist, in male and female rats. Arch. Pharmacol. 355(4):R8 (1997).
H. Berger, N. Heinrich, H. Schäfer, I. Baeger, and B. Mehlis. Gonadotropin-releasing hormone (GnRH) pharmacokinetics: peptide hormone pharmacokinetics needs clarification. Life Sci. 42:985-991 (1988).
N. I. Chu, R. L. Chan, K. M. Hama, and M. D. Chaplin. Disposition of Narfarelin acetate, a potent luteinizing hormone-releasing hormone agonist, in rats and rhesus monkeys. Drug Metab. Dispos. 13:560-565 (1985).
H. Berger, N. Heinrich, E. Albrecht, U. Kertscher, J. Oehlke, M. Bienert, H. Schäfer, I. Baeger, and B. Mehlis. Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. Regul. Pept. 33:299-311 (1991).
E. Ezan, K. Drieu, M. Chapelat, C. Rougeot, and F. Dray. Radioimmunoassay of [D-Trp6]-luteinizing hormone releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. Regul. Pept. 14:155-167 (1986).
H. Okada, Y. Inoue, T. Heya, H. Ueno, Y. Ogawa, and H. Touchi. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8:787-791 (1991).
E. Hudon, J. J. Rondeau, V. Lenaerts, P. Wüthrich, F. Boutignon, R. Deghenghi, S. Marleau, N. Yamagutchi, A. Adam, and H. Ong. Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. J. Pharm. Sci. 86:172-178 (1997).
F. Haviv, E. N. Bush, J. Knittle, and J. Greer. LHRH Antagonists. In Borchard (eds), Integration of pharmaceutical discovery and development, Plenum Press, New York, 1998.
S. Sorensen, J. J. Rondeau, V. Lenaerts, F. Boutignon, P. Wüthrich, R. Deghenghi, A. Adam, and H. Ong. Radioimmunoassay of antarelix, a luteinising hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. J. Immunoassay 17:205-226 (1996).
R. L. Chan, W. Ho, A. S. Webb, J. A. LaFargue, and C. A. Nerenberg. Disposition of detirelix, a potent luteinising hormone-releasing hormone antagonist, in rats and monkeys. Pharm. Res. 5:335-340 (1988).
R. L. Chan, S. C. Hsieh, P. E. Haroldsen, W. Ho, and J. J. Nestor, Jr. Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. Drug Metab. Dispos. 19:858-864 (1991).
V. J. Csernus, B. Szende, K. Groot, T. W. Redding, and A. V. Schally. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Drug Res. 40: 111-118 (1990).
H. H. Raffel, M. Locher, H. O. Borbe. High-performance liquid chromatographic assay for the determination of the decapeptide cetrorelix, a novel luteinizing hormone-releasing hormone antagonist, in human plasma. J Chromatography B. 653:102-105 (1994).
M. Gibaldi and D. Perrier. Pharmacokinetics. 2nd Ed. Marcel Dekker Inc., 1982, pp. 155-161.
N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin Biopharm. 21:457-478 (1993).
F. Mentre and R. Gomeni. A two step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J. Biopharm. Stat. 5:141-158 (1995).
User Manual, P-Pharm, (Ver. 1.5), Innaphase, Champs sur Marne, France (1994).
A. Bartke, R. E. Steele, N. Musto, and B. V. Caldwell. Fluctuations in plasma testosterone levels in adult male rats and mice. Endocrinol. 92:1223-1228 (1973).
A. R. Günzel-Apel, H. G. Brinckmann, and H. O. Hoppen. Dynamics of LH and testosterone secretion in male beagles of different age. Reprod. Dom. Anim. 25:78-86 (1990).
J-M. Gries, A. Munafo, H. C. Porchet, and D. Verotta. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J. Pharmacol. Exp. Ther. 289:371-377 (1999).
G. Halmos, A. V. Schally, J. Pinski, M. Vadillo-Buenfil, and K. Groot. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA 93:2398-2402 (1996).
K. E. Fattinger, D. Verotta, H. C. Porchet, A. Munafo, J-Y. Le Cotonnec, and L. B. Sheiner. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am. J. Physiol. 271:E775-E787 (1996).
A. Lasdun, S. Reznik, C. J. Molineaux, and M. Orlowski. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone. J. Pharmacol. Exp. Ther. 251:439-447 (1989).
B. Horsthemke, H. Knisatschek, J. Rivier, J. Sandow, and K. Bauer. Degradation of luteinizing hormone-releasing hormone and analogs by adeno-hypophyseal peptidases. Biochem. Biophys. Res. Commun. 100:753-759 (1981).
K. Hakola, D. Pierroz, A. Aebi, B. A. M. Vuagnat, M. L. Aubert, and I. Huhtaniemi. Dose and time relationship of intravenously injected rat recombinant luteinizing hormone and testicular testosterone secretion in the male rat. Biol. Reproduction 59:338-343 (1998).
B. W. Knol, S. J. Dielemann, M. M. Bevers, and W. E. van den Brom. GnRH in the male dog: dose-response relationship with LH and testosterone. J. Reprod. Fert. 98:159-161 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwahn, M., Nagaraja, N.V. & Derendorf, H. Population Pharmacokinetic/ Pharmacodynamic Modeling of Cetrorelix, a Novel LH-RH Antagonist, and Testosterone in Rats and Dogs. Pharm Res 17, 328–335 (2000). https://doi.org/10.1023/A:1007557207590
Issue Date:
DOI: https://doi.org/10.1023/A:1007557207590